chinese-drug-maker-seeks-hong-kong-listing

Chinese drug maker seeks Hong Kong listing

IPO investors will need to weigh up United Laboratories' strong structural growth potential and generous valuation against a regulated market with plenty of competition and price controls.
The United Laboratories International TUL has started marketing an initial public offering of up to HK$825 million $105 million, which gives investors yet another chance to gain exposure to ChinaÆs rapidly growing, but heavily regulated, market for pharmaceuticals.

Sources close to the offering say the key selling points for the Chinese manufacturer of generic Western drugs will be its vertically integrated business model which gives it better control over product quality and production costs and also ensures higher margins versus most of its industry peers. It also has a well-recognised brand name, an extensive sales and marketing network and a strong pipeline of 26 new drugs that are expected to come to market...
¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222